Printer Friendly

GSK confirms deal with Dermavent Sciences.

M2 EQUITYBITES-July 13, 2018-GSK confirms deal with Dermavent Sciences

(C)2018 M2 COMMUNICATIONS http://www.m2.com

GlaxoSmithKline (LON: GSK) will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences' subsidiary Dermavent Sciences, Pharmafile reported on Friday.

Dermavent paid an upfront payment of GBP150 for the rights to tapinarof. It has also agreed to pay GSK future milestone payments of an additional GBP100m upon the achievement of prespecified developmental targets.

Completion of the deal will give Dermavent the global rights to the drug in all countries except China.

The drug has been studied as a treatment for psoriasis and atopic dermatitis (eczema). It was found to have demonstrated clinically meaningful results in treating adults with plaque psoriasis in a Phase IIb study involving 227 patients.

A separate double-blind, placebo-controlled Phase IIb study involving 247 patients with atopic dermatitis also resulted in the drug demonstrating efficacy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 13, 2018
Words:159
Previous Article:Equity Commonwealth announces preferred stock dividends of USD0.40625 per share.
Next Article:Capio's board rejects the public cash offer of SEK48.5 per share from Ramsay GenA(c)rale de SantA(c).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters